Researchers who evaluated how long someone is impaired after cannabis use, say their findings suggest current drug-driving laws may be “unjust”.
The findings raise questions about current drug-driving laws across the world, which penalise for THC presence, not intoxication levels, researchers say.
A comprehensive analysis of 80 scientific studies has identified a ‘window of impairment’ of between three and 10 hours caused by moderate to high doses of the intoxicating component of cannabis, tetrahydrocannabinol (THC).
The study found the exact duration of impairment depends on the dose of THC, whether the THC is inhaled or taken orally, whether the cannabis user is regular or occasional and the demands of the task being undertaken while intoxicated.
Published in Neuroscience & Biobehavioral Reviews, the study represents the first such meta-analysis and distilled the results of 80 separate scientific studies into THC-induced impairment conducted over the past 20 years.
“Legal cannabis use, both medical and non-medical, is increasingly common across the world,” said lead author Dr Danielle McCartney from the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.
“THC is known to acutely impair driving and cognitive performance but many users are unsure how long this impairment lasts and when they can resume safety-sensitive tasks, such as driving, after cannabis consumption.
“Our analysis indicates that impairment may last up to 10 hours if high doses of THC are consumed orally. A more typical duration of impairment, however, is four hours, when lower doses of THC are consumed via smoking or vaporisation and simpler tasks are undertaken (e.g., those using cognitive skills such as reaction time, sustained attention and working memory).
“This impairment may extend up to six or seven hours if higher doses of THC are inhaled and complex tasks, such as driving, are assessed.”
For this study a moderate THC dose is about 10mg, but researchers say what is moderate for a regular user could be high for those who only consume occasionally.
Co-author Dr Thomas Arkell, also from the Lambert Initiative, said: “We found that impairment is much more predictable in occasional cannabis users than regular cannabis users. Heavy users show significant tolerance to the effects of cannabis on driving and cognitive function, while typically displaying some impairment.”
The authors noted that regular users might consume more cannabis to achieve an effect, leading to an equivalent amount of impairment.
Many medicinal cannabis users consume THC in the form of oils, sprays or capsules and another important finding was that with such oral use the impairment takes longer to appear and lasts significantly longer than with inhaling.
Researchers said that the findings have implications for so-called drug-driving laws.
Academic director of the Lambert Initiative, Professor Iain McGregor, said: “THC can be detected in the body weeks after cannabis consumption while it is clear that impairment lasts for a much shorter period of time. Our legal frameworks probably need to catch up with that and, as with alcohol, focus on the interval when users are more of a risk to themselves and others. Prosecution solely on the basis of the presence of THC in blood or saliva is manifestly unjust.”
He added: “Laws should be about safety on the roads, not arbitrary punishment. Given that cannabis is legal in an increasing number of jurisdictions, we need an evidence-based approach to drug-driving laws.”
This paper follows recent research by Dr Arkell and colleagues that shows one of the medically active components of cannabis, cannabidiol (CBD) does not cause impairment in driving.
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
New report calls for overhaul of ‘discriminatory’ UK cannabis driving laws
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure